PTGX icon

Protagonist Therapeutics
PTGX

Overview Fund Activity

129 hedge funds and large institutions have $398M invested in Protagonist Therapeutics in 2022 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 40 increasing their positions, 40 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
129
Holders Change
–
Holders Change %
0%
% of All Funds
2.23%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
29
Increased
40
Reduced
40
Closed
29
Calls
$7.01M
Puts
$858K
Net Calls
+$6.16M
Net Calls Change
-$7.64M

Top Buyers

1
Citadel Advisors
1
Citadel Advisors
Florida
$7.3M
2
KCM
2
Kynam Capital Management
New Jersey
$4.38M
3
Morgan Stanley
3
Morgan Stanley
New York
$18.8M
4
Marshall Wace
4
Marshall Wace
United Kingdom
$6.87M
5
Jacobs Levy Equity Management
5
Jacobs Levy Equity Management
New Jersey
$2.14M

Top Sellers

1
State Street
1
State Street
Massachusetts
$39.4M
2
Point72 Asset Management
2
Point72 Asset Management
Connecticut
$21.4M
3
BI
3
BVF Inc
California
$0
4
CAC
4
Cowen and Company
New York
$0
5
Millennium Management
5
Millennium Management
New York
$1.67M
Name Holding Trade Value Shares
Change 		Shares
Change %
QT
151
Quantamental Technologies
New York
– -$88K -11,170 Closed
CC
152
Corton Capital
Ontario, Canada
– -$86K -10,836 Closed
AI
153
Atom Investors
Texas
– -$82K -10,338 Closed
EBA
154
Eagle Bay Advisors
New York
– -$7.91K -1,000 Closed
IBT
155
International Biotechnology Trust
United Kingdom
– -$16.2K -128 Closed
Federated Hermes
156
Federated Hermes
Pennsylvania
– -$1K -28 Closed
3 4 5 6
7